Understanding how genetic and environmental factors affect resistance to cancer treatment in esophageal adenocarcinoma
Official title: Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma
Funded at University of Tx Md Anderson Can Ctr · NIH-10917384 · Data updated 2026-11-12
This study is looking into why some people with esophageal adenocarcinoma don’t respond well to chemoradiation therapy, by examining their tumor samples to find out what genetic and environmental factors might be making the treatment less effective, with the hope of improving future treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $263,522 |
| NIH project number | 5U54CA274220-03 |
| Project ID | NIH-10917384 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with esophageal adenocarcinoma who are about to undergo chemoradiation therapy.
✕Less likely to help
Patients with other types of cancer or those who are not undergoing chemoradiation therapy may not benefit from this research.
What this research studies
This research investigates the reasons why some patients with esophageal adenocarcinoma do not respond to chemoradiation therapy. By analyzing tumor samples collected from patients before and during treatment, the study aims to identify specific genetic and environmental factors that contribute to resistance against a type of cell death called ferroptosis, which is important for the effectiveness of the therapy. The researchers will use advanced techniques like single cell transcriptome profiling to explore the interactions between cancer cells and their surrounding environment, providing insights that could lead to better predictive tools for treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with esophageal adenocarcinoma, enhancing their chances of responding to therapy.
How similar studies have gone: Other research has shown promise in understanding cancer treatment resistance through similar genomic and microenvironmental analyses, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Lin, Steven Hsesheng — University of Tx Md Anderson Can Ctr
- Study coordinator: Lin, Steven Hsesheng
Related research
Other NIH-funded projects on the same topics.
-
Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer
A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.
-
Overcoming Immunotherapy Resistance in Metastatic Gastric/Esophageal Cancer
A Mayo Clinic-led study aims to find better combos of immune therapy and standard treatment to help people with metastatic gastric and esophageal cancer who don’t respond well to current options.
-
NEK2's role in esophageal cancer development
A study looking at how the NEK2 protein contributes to the development and progression of esophageal adenocarcinoma in conditions like Barrett’s esophagus.
-
Understanding why some esophageal cancer patients don’t respond to chemoradiation
A research project at MD Anderson is looking at why esophageal cancer patients often don’t fully respond to chemoradiation and how tumor biology and the surrounding environment affect treatment.
-
AI-powered screening to detect Barrett’s esophagus and early esophageal cancer
A Mayo Clinic team is testing an AI-assisted tool that uses health data to identify people at risk for Barrett’s esophagus and early esophageal cancer so they can get timely endoscopic evaluation.
-
SOX4-driven transcription in esophageal cancer
Researchers are studying how a specific gene network drives esophageal cancer that can arise from Barrett's esophagus, aiming to uncover new targets for therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.